Protocol Ledger

NCT07285655 · Phase III · RECRUITING

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

Interventional Phase III clinical trial protocol NCT07285655 sponsored by Liquidia Technologies in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-23 Enrollment: 344 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07285655
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)344 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07285655
Protocol FieldVerified Registry Value
NCT IdentifierNCT07285655
Consolidated Lead SponsorLiquidia Technologies
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment344 participants (ESTIMATED)
Registered Start Date2026-04-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI